Hepatotoxicity associated with lapatinib in an experimental rat model

European Journal of Cancer

Volumn 48, Issue 2, 2012, Pages 279-285

  Demirci, Umut ^a   Buyukberber, Suleyman ^b   Yilmaz, Guldal ^b   Kerem, Mustafa ^b   Coskun, Ugur ^b   Uner, Aytug ^b   Baykara, Meltem ^b   Pasali, Hatice ^b   Benekli, Mustafa ^b  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Hepatotoxicity; Lapatinib; Rat

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; LACTATE DEHYDROGENASE; LAPATINIB; STERILE WATER; TRIACYLGLYCEROL; URIC ACID; VERY LOW DENSITY LIPOPROTEIN;

ACINAR CELL; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CELL DEGENERATION; CELL VACUOLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EOSINOPHIL; EXPERIMENTAL RAT; FEEDING; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; INFLAMMATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE; LIPOPROTEIN BLOOD LEVEL; LIVER CELL; LIVER PARENCHYMA; LIVER TOXICITY; MONONUCLEAR CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; WISTAR ALBINO GLAXO RAT;

ALANINE TRANSAMINASE; ALBUMINS; ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; LIPOPROTEINS, VLDL; LIVER; LIVER FUNCTION TESTS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES;

EID: 84655163857     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.10.011     Document Type: Article

References (37)

1. G. Atalay, F. Cardoso, A. Awada, and M.J. Piccart Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer Ann Onc 14 2003 1346 1363 (Pubitemid 37185280)
2. D.F. Stern Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases Breast Cancer Res 2 2000 176 183 (Pubitemid 32223582)
3. G. Demonty, C. Bernard-Marty, F. Puglisi, I. Mancini, and M. Piccart Progress and new standards of care in the management of HER-2 positive breast cancer Eur J Cancer 43 2007 497 509 (Pubitemid 46177593)
4. A. Citri, and Y. Yarden EGF-ERBB signalling: towards the systems level Nat Rev Mol Cell Biol 7 2006 505 516 (Pubitemid 44036456)
5. J.S. Ross, E.A. Slodkowska, and W.F. Symmans The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 14 2009 320 368
6. J.G.M. Klijn, P.M.J.J. Berns, P.L.M. Schmits, and J.A. Foekens The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients Endocr Rev 13 1992 3 17
7. E.H. Romond, E.A. Perez, and J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684 (Pubitemid 41464706)
8. M.J. Piccart-Gebhart, M. Procter, and B. Leyland-Jones Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672 (Pubitemid 41464705)
9. H. Joensuu, P.L. Kellokumpu-Lehtinen, and P. Bono Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 2006 809 820 (Pubitemid 43290919)
10. D.W. Rusnak, K. Lackey, and K. Affleck The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW572016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo Mol Cancer Ther 1 2001 85 94
11. D.J. Riese 2nd, and D.F. Stern Specificity within the EGF family/ErbB receptor family signaling network Bioessays 20 1998 41 48 (Pubitemid 28111330)
12. J. Okano, I. Gaslightwala, M.J. Birnbaum, A.K. Rustgi, and H. Nakagawa Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation J Biol Chem 275 2000 30934 30942
13. C.E. Geyer, J. Forster, and D. Lindquist Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 55 2006 2733 2743 (Pubitemid 46021510)
14. J.W. Polli, J.E. Humphreys, and K.A. Harmon The role of efflux and uptake transporters in N-{3-chloro-[(3-fluorobenzyl)oxy]phenyl}-6-[5- ({[2(methylsulfonyl) ethyl] amino}methyl)-2-furyl]-4quinazolinamine(GW572016, lapatinib) disposition and drug interactions Drug Metab Dispos 36 2008 695 701 (Pubitemid 351468376)
15. D. Zorzi, A. Laurent, and T.M. Pawlik Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases Br J Surg 94 2007 274 286 (Pubitemid 46423843)
16. A.P. Schouten van der Velden, C.J. Punt, J.H. Van Krieken, V.A. Derleyn, and T.J. Ruers Hepatic veno-occlusive disease after neoadjuvant treatment of colorectal liver metastases with oxaliplatin: a lesson of the month Eur J Surg Oncol 34 2008 353 355 (Pubitemid 351312859)
17. Y. Loriot, G. Perlemuter, and D. Malka Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy Nat Clin Pract Oncol 5 2008 268 278 (Pubitemid 351594143)
18. H. Burger, H. van Tol, and M. Brok Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps Cancer Biol Ther 4 2005 747 752 (Pubitemid 41351174)
19. D. Ribero, H. Wang, and M. Donadon Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases Cancer 110 2007 2761 2767 (Pubitemid 350250347)
20. M. Klinger, S. Eipeldauer, and S. Hacker Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases Eur J Surg Oncol 35 2009 515 520
21. P.J. Medina, and S. Goodin Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases Clin Ther 30 2008 1426 1447
22. H.A. Burris 3rd, H.I. Hurwitz, and E.C. Dees Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas J Clin Oncol 23 2005 5305 5313 (Pubitemid 46206984)
23. M. Toi, H. Iwata, and Y. Fujiwara Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies Br J Cancer 10 2009 1676 1682
24. B. Moy, E. Rappold, and L. Williams Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib J Clin Oncol 27 2009 1043 [abstr.]
25. C.F. Spraggs, L.R. Budde, and L.P. Briley HLA-DQA102:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer J Clin Oncol 29 2011 667 673
26. A. Pariente, F. Etcharry, and V. Cales Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour Eur J Gastroenterol Hepatol 18 2006 785 787
27. P. Rajvanshi, H.M. Shulman, E.L. Sievers, and G.B. McDonald Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy Blood 99 2002 2310 2314 (Pubitemid 34525414)
28. N.U. Lin, S. Sarantopoulos, and J.R. Stone Fatal hepatic necrosis following imatinib mesylate therapy Blood 102 2003 3455 3456 (Pubitemid 37314789)
29. K. Ohyashiki, Y. Kuriyama, and A. Nakajima Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis Leukemia 16 2002 2160 2161 (Pubitemid 35203464)
30. C. Ho, J. Davis, F. Anderson, G. Bebb, and N. Murray Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib J Clin Oncol 23 2005 8531 8533
31. J.P. Jani, R.S. Finn, and M. Campbell Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor Cancer Res 67 2007 9887 9893 (Pubitemid 47621237)
32. W. Jager, E. Gehring, and B. Hagenauer Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of the multidrug resistance protein 2 (Mrp2) Life Sci 73 2003 2841 2854 (Pubitemid 37153358)
33. B. Nordlinger, and S. Benoist Benefits and risks of neoadjuvant therapy for liver metastases J Clin Oncol 24 2006 4954 4955 (Pubitemid 46631395)
34. T. Aloia, M. Sebagh, and M. Plasse Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases J Clin Oncol 24 2006 4983 4990 (Pubitemid 46631400)
35. N.N. Mehta, R. Ravikumar, and C.A. Coldham Effect of preoperative chemotherapy on liver resection for colorectal liver metastases Eur J Surg Oncol 34 2008 782 786
36. H. Nakano, E. Oussoultzoglou, and E. Rosso Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy Ann Surg 247 2008 118 124
37. J.M. McKoy, C. Angelotta, and C.L. Bennett Gemtuzumab ozogamicin associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project Leuk Res 31 2007 599 604 (Pubitemid 46578145)